One of the primary causes of heart disease is high cholesterol which clogs the coronary arteries.
“Our goal is to reduce or eliminate risk factors that increase the likelihood of clogged coronary arteries – called atherosclerosis. Fortunately, it is often possible to lower cholesterol levels leading to atherosclerosis, even in patients with extremely high cholesterol levels..”
Bruce Gordon, MD
Director Comprehensive Lipid Control Center
The CLCC provides coordinated and comprehensive care for adults and children with the most severe forms of high cholesterol, including familial hypercholesterolemia. Our goal is to detect and eliminate risk factors for atherosclerosis and prevent heart disease. Rogosin has an internationally renowned research group that performs basic and clinical research in the lipid field.
Rogosin’s work in lipid control began in the early 1980s when The Institute collaborated with The Rockefeller University to pioneer clinical research of LDL-apheresis, a procedure that lowers “bad” LDL cholesterol, the major cholesterol carrying lipoprotein in the blood, by more than 50%, while sparing the “good” HDL cholesterol. The process involves taking blood from the body to remove the LDL-cholesterol, and then returning it back to the body in an easily tolerated procedure that has benefited many thousands of patients. Rogosin’s clinical work contributed to the 1996 FDA approval of the LDL-apheresis procedure developed by Kaneka America Corp.
The CLCC at Rogosin was the first LDL-apheresis unit in the United States and it continues to treat children and adults with severe familial hypercholesterolemia. In addition to LDL-apheresis, the CLCC provides a full range of diagnostic and treatment services for adults and children. Individualized treatment at the CLCC may include diet and exercise modification, lipid lowering medication and when necessary, referral for other therapy.
Diet and exercise play an important role in the production and elimination of cholesterol. The nutritionists with the Maurice R. Greenberg Comprehensive Lipid Control Center develop diet programs that are designed to improve each person’s lipid profile and overall health. They have decades of experience in teaching patients how to successfully improve their lipid profiles.
The CLCC is located within the Jack Dreyfus outpatient facility at The Rogosin Institute, 505 East 70th street, second floor. For more information about the CLCC, call 212-746-1554
Make an appointment
The Pediatric CLCC (PCLCC) was established in 1989 to diagnose and treat children with inherited causes of extremely high cholesterol or triglyceride levels as early in life as possible. Early intervention can prevent conditions such as diabetes, kidney disease, heart disease, and obesity that are so difficult to treat in adulthood.
Lisa Hudgins, MD, director of the PCLCC, believes that children with risk factors for atherosclerosis need to be identified early and receive appropriate treatment.
Most children with lipid disorders can be treated with lifestyle counseling, such as diet and exercise. Medications are only used when diet and exercise are not effective. However, some with common genetic conditions may require medication by their teen years. One example is heterozygous familial hypercholesterolemia (FH), a condition that results when children inherit and abnormal gene from one parent or another. In FH, cholesterol levels are elevated from birth and are usually resistant to changes in diet.
Dr. Hudgins is recognized as one of the foremost authorities on treating children with homozygous FH. Untreated, these patients have LDL cholesterol levels above 500 mg/dL and can have heart attacks and die suddenly in adolescence or early childhood. These children are resistant to diet and exercise but newer cholesterol lowering medications maybe helpful. Many patients need LDL-apheresis, a procedure pioneered at Rogosin that takes blood outside the body, removes the LDL-cholesterol and returns the blood back to the body. For children who do not respond to LDL-apheresis, liver transplantation, performed in collaboration with the NewYork-Presbyterian/Columbia Center for Liver Disease and Transplantation, is an option.
For more information contact Lisa Hudgins, MD, at 212-746-6972. Make an appointment